Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Single cell transcriptomes of brain metastases and micrometastases derived from triple negative human breast cancer cell line in mouse model.

ABSTRACT: Single cell transcriptomes of brain metastases and micrometastases derived from triple negative human breast cancer cell line in mouse model.

PROVIDER: PRJNA640555 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12053587_1.fastq.gz	Fastqsanger.gz
	SRR12053587_2.fastq.gz	Fastqsanger.gz
	SRR12053588_1.fastq.gz	Fastqsanger.gz
	SRR12053588_2.fastq.gz	Fastqsanger.gz
	SRR12053589_1.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 12

Similar Datasets

Expression Profiling of a Mouse Xenograft Model of “Triple-Negative” Breast Cancer Brain Metastases With Vorinostat

Project description:Gene Expression Profiling of a Mouse Xenograft Model of “Triple-Negative” Breast Cancer Brain Metastases With and Without Vorinostat Treatment. Purpose: As chemotherapy and molecular therapy improve the systemic survival of breast cancer patients, the incidence of brain metastases increases. Few therapeutic strategies exist for the treatment of brain metastases because the blood-brain barrier severely limits drug access. We report the pharmacokinetic, efficacy, and mechanism of action studies for the histone deactylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in a preclinical model of brain metastasis of triple-negative breast cancer. Experimental Design: The 231-BR brain trophic subline of the MDA-MB-231 human breast cancer cell line was injected into immunocompromised mice for pharmacokinetic and metastasis studies. Pharmacodynamic studies compared histone acetylation, apoptosis, proliferation, and DNA damage in vitro and in vivo. Results: Following systemic administration, uptake of [14C]vorinostat was significant into normal rodent brain and accumulation was up to 3-fold higher in a proportion of metastases formed by 231-BR cells. Vorinostat prevented the development of 231-BR micrometastases by 28% (P = 0.017) and large metastases by 62% (P < 0.0001) compared with vehicle-treated mice when treatment was initiated on day 3 post-injection. The inhibitory activity of vorinostat as a single agent was linked to a novel function in vivo: induction of DNA double-strand breaks associated with the down-regulation of the DNA repair gene Rad52. Conclusions: We report the first preclinical data for the prevention of brain metastasis of triple-negative breast cancer. Vorinostat is brain permeable and can prevent the formation of brain metastases by 62%. Its mechanism of action involves the induction of DNA double-strand breaks, suggesting rational combinations with DNA active drugs or radiation.

2009-10-14 | GSE18544 | GEO

Immunosuppressive microenvironment restrains chemotherapy efficacy in liver metastases of triple-negative breast cancer

Project description:This study investigates the role of the immune microenvironment in the efficacy of chemotherapy for triple-negative breast cancer (TNBC) liver metastases compared to primary tumors. Using mouse models, we assessed chemotherapeutic efficacy and characterized intratumoral T lymphocytes and macrophages via RNA sequencing, immunohistochemistry, and flow cytometry. We found that liver metastases had a less effective response to chemotherapy compared to subcutaneous tumors, linked to reduced CD8+ T cell infiltration and macrophage activation. Chemotherapy induced an immunosuppressive shift, with neutrophil extracellular traps (NETs) accumulating in liver metastases and macrophages and T cells showing impaired functionality in the primary tumors. Combining macrophage activators or NETs inhibitors with chemotherapy improved outcomes. Our findings highlight the importance of tumor site-specific immune microenvironmental differences in chemotherapy responses and suggest that targeted therapies could enhance chemotherapy efficacy.

2025-06-25 | GSE276098 | GEO

Immunosuppressive microenvironment restrains chemotherapy efficacy in liver metastases of triple-negative breast cancer

Project description:Immunosuppressive microenvironment restrains chemotherapy efficacy in liver metastases of triple-negative breast cancer

| PRJNA1154683 | ENA

Decreased expression of key tumour suppressor microRNAs is associated with lymph node metastases in triple negative breast cancer

Project description:Breast cancer is the most common malignancy that develops in women, responsible for the highest cancer-associated death rates. Triple negative breast cancers (TNBC) represent an important subtype that have an aggressive clinical phenotype, are associated with a higher likelihood of metastasis and are not responsive to current targeted therapies. miRNAs have emerged as an attractive candidate for molecular biomarkers and treatment targets in breast cancer, but their role in the progression of TNBC remains largely unexplored. This study has investigated miRNA expression profiles in 31 primary TNBC cases and in 13 lymph node metastases compared with 23 matched normal breast tissues to determine miRNAs associated with the initiation of this disease subtype and those associated with its metastasis. 71 miRNAs were differentially expressed in TNBC, the majority of which have previously been associated with breast cancer, including members of the miR-200 family and the miR-17-92 oncogenic cluster, suggesting that miRNAs involved in the initiation of TNBC are not subtype specific. However, the repertoire of miRNAs expressed in lymph node negative and lymph node positive TNBCs were largely distinct from one another. In particular, miRNA profiles associated with lymph node negative disease tended to be up-regulated, while those associated with lymph node positive disease were down-regulated and largely overlapped with the profiles of their matched lymph node metastases. miRNA expression profiles were examined in 31 primary TNBC cases and in 13 lymph node metastases compared with 23 matched normal breast tissues

2014-11-24 | E-GEOD-38167 | biostudies-arrayexpress

ChIP-sequencing of ZEB1 in triple negative breast cancer cell line Hs578T

Project description:This experiment is performed to reveal the novel binding sites of ZEB1 transcription factor globally in triple negative breast cancer cell line Hs578T. We also reveal the effect of TGF cytokine on the binding sites of ZEB1.

2018-04-25 | E-MTAB-5241 | biostudies-arrayexpress

Single cell transcriptomes of brain metastases and micrometastases derived from triple negative human breast cancer cell line in mouse model.

Project description:In order to gainan understanding of potential mechanisms by which dystroglycan could effect DTC quiescence signaling in brain, we took an unbiased approach. We inoculated a series of mice with a tdTomato-positive, brain metastatic variant of T4-2 cells, and examined mice after 6-weeks in order to identify those with distinct brain metastases. Metastatic lesions were surgically dissected, digested and flow sorted to purify tdTomato+ cells (“Metastases”). In parallel, the remaining uninvolved brain was digested, and residual tdTomato+tumour cells were purified from this digest via flow sorting (“Micromets”). These two populations were indexed, and the libraries were prepared following standard 10X Genomics protocols.

2021-10-05 | GSE152818 | GEO

Transcriptomes of triple negative breast cancer enriched breast cancer cohort

Project description:Breast cancers enriched for the triple negative breast cancer phenotype with extensive clinico-pathological features were profiled to establish their comprehensive transcriptional profiles

2016-11-21 | E-MTAB-5270 | biostudies-arrayexpress

Role of CCN3 on Hs578T triple negative breast cancer cell line

Project description:Role of CCN3 on Hs578T triple negative breast cancer cell line

| PRJNA796001 | ENA

Triple-negative breast cancer cell line MDA-MB-231 +/- CD43 knockdown

Project description:Triple-negative breast cancer cell line MDA-MB-231 +/- CD43 knockdown

| PRJNA726972 | ENA

SMAD2 binding regions in triple negative breast cancer cell line, Hs578T

Project description:SMAD2 binding regions in triple negative breast cancer cell line, Hs578T

| PRJNA482343 | ENA